Please provide your email address to receive an email when new articles are posted on . Sozinibercept, a VEGF-C and -D “trap” inhibitor, showed improved durability in patients with retinal diseases ...

Retinal and choroidal vascular diseases are principal causes of blindness for adults in developed countries around the world. Neovascular age-related macular degeneration (nAMD) and diabetic macular ...

Please provide your email address to receive an email when new articles are posted on . The clinical trials have purposefully strict inclusion and exclusion criteria to control the variables that ...

This story is part of a series on the current progression in Regenerative Medicine. This piece is part of a series dedicated to the eye and improvements in restoring vision. In 1999, I defined ...

Individuals in Taiwan who suffer from migraine were at an increased risk of developing neovascular age-related macular degeneration. Individuals suffering from migraine have a 20% increased risk of ...

Patients assigned to SRT received an average of 10.7 doses of ranibizumab (Lucentis) over 2 years as compared with 13.3 for patients assigned to sham SRT. Best-corrected visual acuity (BCVA) did not ...

People who take the oral biguanide metformin have a 5% lower odds of developing age-related macular degeneration (AMD) than people who do not use the diabetes drug. The study included 86,930 patients ...

The therapy is expected to block abnormal blood vessel growth, limit vascular leakage, and reduce retina damage. The Food and Drug Administration (FDA) has granted Fast Track designation to SAR402663 ...

Neovascular age-related macular degeneration (nAMD) is a progressive eye disease characterized by choroidal neovascularization and subretinal hemorrhage and exudation, leading to vision impairment.

CHICAGO -- An artificial intelligence (AI)-based study of home monitoring for neovascular age-related macular degeneration (AMD) suggested a potential annual savings of $3,200 per patient, with ...